Average Target Price for Japan Tobacco Increases 7.54%

Market by 2FIRSTS.ai
Dec.18.2023
Average Target Price for Japan Tobacco Increases 7.54%
The average target price for Japan Tobacco has been revised to $23.43, a 7.54% increase since August 1.

According to investment platform Fintel, recent reports have shown that the average one-year target price for Japan Tobacco (OTC:JAPAF) has been revised to $23.43 per share, representing a 7.54% increase from the valuation of $21.78 per share on August 1, 2023.

 

The target price is the average forecast provided by numerous analysts. The latest target price range is from a low of $15.69 per share to a high of $28.92 per share. This average target price represents a decrease of 7.33% from the recent closing price of $25.28 per share.

 

Furthermore, 334 funds or institutions were reported to hold shares of Japan Tobacco, a decrease of 5 or 1.47% from the previous quarter. The average holding ratio of all funds investing in Japan Tobacco was 0.37%, a decrease of 0.21% compared to the previous quarter. The total number of shares held by institutions increased by 0.95% in the past three months to reach 108,634K shares.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global Appoints Former BAT Global Head of Strategy James Yamanaka as Chief Executive Officer
Organigram Global has named James Yamanaka, previously Global Head of Strategy at British American Tobacco (BTI), as its new CEO. His appointment is expected to take effect around January 15, 2026, and he will also join the company’s board. Yamanaka brings more than 20 years of strategic and managerial experience from roles across Europe and Asia at BTI.
Nov.26
Philippine DOH Calls for Nationwide Vape Ban Amid Surging Youth Use
Philippine DOH Calls for Nationwide Vape Ban Amid Surging Youth Use
The Philippine Department of Health (DOH) has warned that youth vaping has reached alarming levels. Health Secretary Ted Herbosa stressed that despite regulations limiting vaping to adults aged 18 and above, minors—many in school uniforms—are frequently seen using vape devices. Criticizing the industry’s youth-targeted marketing tactics, Herbosa said the government should consider a nationwide total ban on vape products.
Nov.24 by 2FIRSTS.ai
Ispire and IKE Tech Welcome FDA Enforcement Boost, Highlight Need for Tech-Based Controls
Ispire and IKE Tech Welcome FDA Enforcement Boost, Highlight Need for Tech-Based Controls
Ispire Technology and IKE Tech issued statements after the U.S. FDA received Congressional funding and directives to strengthen enforcement against illicit vaping products. The companies emphasized updated guidance, multi-agency coordination and the role of blockchain and age-verification technologies in preventing illegal imports and protecting youth.
Nov.20
Irish Vape Group Urges Full Scrutiny of Single-Use Vape Bill
Irish Vape Group Urges Full Scrutiny of Single-Use Vape Bill
Responsible Vaping Ireland (RVI) has urged TDs to fully scrutinise the Public Health (Single-Use Vapes) Bill 2025 as it comes before the Dáil for debate. Representing more than 3,300 independent vape retailers, RVI stressed that meaningful consultation with retailers and enforcement authorities is essential to ensure the ban meets its public health and environmental goals without unintended consequences.
Dec.17 by 2FIRSTS.ai
Mexico Passes Law Banning Commercial Sale and Advertising of Vapes and E-Cigarettes
Mexico Passes Law Banning Commercial Sale and Advertising of Vapes and E-Cigarettes
Mexico’s Chamber of Deputies approved a constitutional reform prohibiting the production, import, export, transport, distribution, sale, and advertising of vapes and e-cigarettes nationwide. The law does not ban personal use of such products. Backed by President Claudia Sheinbaum, the amendment to the General Health Law imposes penalties of one to eight years in prison and fines between 11,314 and 226,280 pesos (approximately USD 621–12,430).
Dec.10 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai